DOI: 10.12890/2020_001946

Rare Features of Dermatomyositis in a Patient with Ovarian Cancer

Authors

  • Lissandra Dal Lago Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  • Frédéric Vandergheynst Internal Medicine Department, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
  • Ahmad Awada Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  • Thierry Pepersack Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

thierry.pepersack@bordet.be

Keywords

Paraneoplastic syndrome, dermatomyositis, Evans’ syndrome, ovarian neoplasm

Abstract

Despite a classical presentation of dermatomyositis, a patient with ovarian cancer had several uncommon features: (i) unexpected onset of dermatomyositis in spite of cancer remission, (ii) development of Evans’ syndrome and subcutaneous edema, and (iii) dysphagia. We discuss the occurrence of these clinical situations as well as the treatments.

View the entire article

Downloads

References

  1. Flynn M, Ottaway Z, Kaur J, Waters J. Three differently timed presentations of dermatomyositis associated with advanced ovarian cancer. BMJ Case Rep 2018;2018:bcr2017222627.
  2. Gao S, Zhu H, Yang H, Zhang H, Li Q, Luo H. The role and mechanism of cathepsin G in dermatomyositis. Biomed Pharmacother 2017;94:697–704.
  3. Hay EM, Makris M, Winfield J, Winfield DA. Evans' syndrome associated with dermatomyositis. Ann Rheum Dis 1990;49(10):793–794.
  4. Flores-Terry MA, Garcia-Arpa M, Anino-Fernandez J, Minguez-Sanchez MD. Edematous dermatomyositis with probable Evans syndrome. Actas Dermosifiliogr 2017;108(7):673–675.
  5. Chang DK, Yoo DH, Kim TH, Jun JB, Lee IH, Bae SC, et al. Induction of remission with intravenous immunoglobulin and cyclophosphamide in steroid-resistant Evans' syndrome associated with dermatomyositis. Clin Rheumatol 2001;20(1):63–66.
  6. Kurushima S, Horai Y, Umeda M, Kawakami A. Anti-transcription intermediary factor1gamma-antibody-positive dermatomyositis complicated by dysphagia. Intern Med 2017;56(21):2965–2966.
  7. Mugii N, Hasegawa M, Matsushita T, Hamaguchi Y, Oohata S, Okita H, et al. Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS One 2016;11(5):e0154746.
  8. Ogawa-Momohara M, Muro Y, Kono M, Akiyama M. Prognosis of dysphagia in dermatomyositis. Clin Exp Rheumatol 2019;37(1):165.
  9. Kwon KM, Lee JS, Kim YH. A case report of life-threatening acute dysphagia in dermatomyositis: challenges in diagnosis and treatment. Medicine (Baltimore) 2018;97(17):e0508.
  10. Hafejee A, Coulson IH. Dysphagia in dermatomyositis secondary to bladder cancer: rapid response to combined immunoglobulin and methylprednisolone. Clin Exp Dermatol 2005;30(1):93–94.
  11. Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011;78(1):41–44.

Published

2020-12-16

Issue

Vol. 7 No. 12 (2020)

How to Cite

1.
Dal Lago L, Vandergheynst F, Awada A, Pepersack T. Rare Features of Dermatomyositis in a Patient with Ovarian Cancer. EJCRIM [Internet]. 2020 Dec. 16 [cited 2026 Nov. 4];7(12). Available from: https://ejcrim.com/index.php/ejcrim/article/view/1946

Most read articles by the same author(s)